The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
Extended Induction Upadacitinib Safe, Effective for Ulcerative Colitis
Extended induction treatment with upadacitinib 45 mg led to achievement of clinical response in a clinically meaningful proportion of patients with ulcerative colitis who do not respond to 8 weeks of induction therapy.
RBX2660 C Difficile Efficacy Further Demonstrated in Phase 3 Open-Label Study
RBX2660 reduced clostridioides difficile infection recurrence at 8 weeks, with a sustained clinical response through 6 months, in an open-label phase 3 cohort of patients representative of real-world clinical practice.
Induction Guselkumab Effective for Ulcerative Colitis Regardless of Prior Therapy
Treatment with guselkumab resulted in greater improvements across key clinical and endoscopic/histologic outcome measures at week 12 compared with placebo in patients with moderately to severely active ulcerative colitis with or without a history of inadequate response or intolerance to advanced therapy.
Guselkumab/Golimumab Induction Safe and Effective for Ulcerative Colitis
Patients with ulcerative colitis treated with combination induction therapy with guselkumab plus golimumab followed by guselkumab monotherapy achieved higher rates of the several end points at week 38 as compared to either guselkumab or golimumab alone.
Dupilumab Shows Significant Efficacy for EoE in Pooled Analysis
Weekly dupilumab 300 mg versus placebo demonstrated statistically significant, clinically meaningful improvements in histologic and endoscopic outcomes and symptoms in adults and adolescents with eosinophilic esophagitis.
Patients with HIV and NAFLD at an Increased Risk of Cardiovascular Disease
Patients with NAFLD were more likely to have comorbidities, including diabetes, hypertension, chronic respiratory disease, hypothyroidism, chronic kidney disease, sleep apnea, and hyperlipidemia.
High-Dose Maintenance Upadacitinib Lengthens UC Remissions
A 30 mg dose of upadacitinib led to a 1 month longer clinical remission and approximately 20% of patients had less severe disease at 52 weeks, when compared with a 15 mg dose for patients with active ulcerative colitis.